Lucicebtide acetate_product_DataBase

Bioactivity

Lucicebtide acetate is the acetate salt form of Lucicebtide (HY-P10376). Lucicebtide acetate is a selective antagonist for CCAAT/enhancer binding protein β (C/EBPβ). Lucicebtide acetate binds to the leucine zipper domain of C/EBPβ, prevents its dimerization, and ubiquitin-dependently degrades C/EBPβ. Lucicebtide acetate arrests cell cycle at G0/G1 phase. Lucicebtide acetate exhibits cytotoxicity in cancer cells. Lucicebtide acetate exhibits good pharmacokinetic characters and inhibits tumor growth in mouse model[1].

Sequence

d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg}

Shortening

d-{Val-Ala-Glu-Ala-Arg-Glu-Glu-Leu-Glu-Arg-Leu-Glu-Ala-Arg-Leu-Gly-Gln-Ala-Arg-Gly-Glu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Leu-Lys-Leu-Gln-Arg}

Formula

C208H345N69O55S.xC2H4O2

Molar Mass

4724.46 (free base)

Appearance

固体

Transport

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Reference

[1]. Darvishi E, et al., Anticancer Activity of ST101, A Novel Antagonist of CCAAT/Enhancer Binding Protein β. Mol Cancer Ther. 2022 Nov 3;21(11):1632-1644.

PeptideDB

Lucicebtide acetate

CAS: F: C208H345N69O55S.xC2H4O2 W: 4724.46 (free base)